What Are Insulin Delivery Devices?
Insulin delivery devices are medical technologies designed to administer insulin to people with diabetes who cannot produce enough insulin or use it effectively. These devices help regulate blood glucose levels and reduce the risk of diabetes-related complications. The most common insulin delivery devices include:
- Traditional Syringes and Vials
- Insulin Pens (Reusable and Disposable)
- Smart Insulin Pens
- Insulin Pumps
- Patch Pumps
- Automated Insulin Delivery (AID) Systems
- Inhaled Insulin Systems
While these devices vary in complexity and functionality, they all share a common goal: making insulin therapy safer, more accurate, and easier to manage.
Why Are Insulin Delivery Devices Becoming So Important?
The need for better insulin delivery has never been greater. According to the World Health Organization (WHO), 830 million people worldwide were living with diabetes in 2022, a dramatic increase from 200 million in 1990. As the number of patients requiring long-term glucose management continues to rise, the demand for more effective and convenient insulin delivery solutions is growing as well.
Traditional insulin injections remain effective but often require multiple daily doses, careful monitoring, and precise administration. Modern insulin delivery devices, such as smart pens and insulin pumps, help improve dosing accuracy, simplify treatment, and support better glucose control. This makes diabetes management more efficient for both patients and healthcare providers.
As a result, innovation in insulin delivery is no longer focused solely on administering insulin. The industry is now working toward technologies that can automate, personalize, and simplify diabetes management.
Automated Insulin Delivery Systems Are Transforming Diabetes Care
Insulin delivery technology is rapidly evolving from simple injection devices to intelligent, automated systems. One of the biggest breakthroughs is the emergence of Automated Insulin Delivery (AID) systems, often referred to as artificial pancreas systems.
These technologies combine an insulin pump, a Continuous Glucose Monitor (CGM), and an algorithm that automatically adjusts insulin delivery based on real-time glucose readings. By continuously responding to changing glucose levels, they replicate some of the key functions of a healthy pancreas and reduce the need for constant manual dosing decisions. Among commercially available AID systems, the Tandem Mobi and t:slim X2 pumps with Control-IQ technology and the Medtronic MiniMed 780G are among the most widely adopted globally.
Innovation is continuing at a rapid pace. In late 2025, Insulet received FDA clearance for upgrades to its Omnipod 5 platform, one of the fastest-growing tubeless AID systems, including a lower glucose target and enhanced automated insulin adjustments. These improvements reflect the industry's push toward more personalized and autonomous diabetes management.
The market is also exploring needle-free insulin delivery. In May 2026, the FDA expanded approval of Afrezza, an inhaled insulin from MannKind, for children aged six and older. It provides an alternative to multiple daily injections and highlights the industry's focus on improving patient convenience. Altogether, these innovations are moving diabetes care toward a future in which insulin delivery becomes increasingly automated, personalized, and less intrusive.
Key Trends Reshaping Insulin Delivery Devices
As manufacturers continue to push the boundaries of diabetes technology, several trends are emerging that are expected to shape the next generation of insulin delivery devices.
- Miniaturization and Tubeless Design
One of the most visible trends is the move toward small and discreet devices. Insulin delivery devices are becoming lighter, more comfortable, and easier to integrate into daily life.
A recent example is the Tandem Mobi, launched as the company's smallest insulin pump to date. About half the size of many traditional pumps, it can be worn in a pocket, clipped to clothing, or attached directly to the body. This shows the industry's push toward less intrusive diabetes management.
- Connected Diabetes Ecosystems
The future of insulin delivery extends beyond the device itself. Modern insulin devices are increasingly integrated with cloud-based platforms and mobile applications, creating connected diabetes ecosystems.
For example, Dexcom's Share and Follow features allow caregivers and healthcare providers to view glucose data in real time. This level of connectivity enables faster intervention, better monitoring, and more personalized diabetes care.
- Artificial Intelligence and Predictive Dosing
Artificial intelligence is also becoming a key component of diabetes management. Rather than simply responding to glucose changes, next-generation systems are being designed to predict and prevent them.
In 2025, Abbott partnered with Sequel Med Tech to integrate the FreeStyle Libre continuous glucose monitoring platform with the twiist insulin delivery system, enabling more advanced algorithm-driven insulin adjustments. Such collaborations are accelerating the development of predictive dosing systems that can anticipate glucose fluctuations before they occur.
What Does the Future Look Like?
The future of insulin delivery is centered on smarter, more automated, and patient-friendly technologies. As artificial pancreas systems, AI-powered dosing algorithms, wearable pumps, and needle-free insulin options continue to advance, diabetes management is expected to become more precise, convenient, and less burdensome.
This momentum is reflected in the market's strong growth outlook. According to Persistence Market Research, the global insulin delivery device market is projected to grow up to US$31.98 billion by 2032, at a CAGR of 15.5% from 2025 to 2032. As innovation continues, insulin delivery devices are predicted to increasingly evolve from treatment tools into intelligent health management systems, helping patients achieve better outcomes with greater ease and confidence.
